Form 4: Singular Genomics Systems COO Exercises Stock Options and Receives Shares

Jyotsna Ghai, Chief Operating Officer of Singular Genomics Systems, Inc., acquired 250 shares of common stock and 250 shares from vested restricted stock units on November 9, 2024.

Summary

• Jyotsna Ghai, the Chief Operating Officer of Singular Genomics Systems, Inc., executed a transaction involving the company's stock on November 9, 2024.
• Ghai acquired 250 shares of common stock through the settlement of vested Restricted Stock Units (RSUs).
• Additionally, 250 shares were acquired from the vesting of RSUs.
• Following these transactions, Ghai directly owns 2,516 shares of common stock and 3,250 derivative securities (RSUs).

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies. It reflects the vesting schedule of equity-based compensation for the company's executives.

Comparison to Industry Standards

• Stock option and RSU grants are a standard form of compensation for executives in publicly traded companies, particularly in the technology and biotech sectors.
• The vesting schedule of 16 equal quarterly installments over four years is a typical vesting period for RSUs.
• Companies like Illumina, Pacific Biosciences, and Oxford Nanopore also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• The transaction has a minor positive impact on the executive's personal holdings.
• The transaction has no material impact on other stakeholders.

Key Dates

Keywords

Singular Genomics Systems, stock options, restricted stock units, insider trading, executive compensation, form 4, securities, OMIC